NCT03742258 2025-06-18
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
Northwestern University
Phase 1 Completed
Northwestern University
Big Ten Cancer Research Consortium
M.D. Anderson Cancer Center
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc
Calithera Biosciences, Inc